A recent non-clinical study has demonstrated the potential of the therapeutic vaccine RUTI® in treating tuberculosis (TB) in mice. RUTI® has demonstrated remarkable efficacy in reducing lung damage and bacterial burden when administered alone or in combination with standard TB chemotherapy.
These findings mark a significant step forward in the development of more effective TB treatments, potentially transforming the landscape of TB.
Currently, Archivel farma is carrying out phase II clinical trials in Ukraine, India and Argentina to explore the potential of RUTI® vaccination in active tuberculosis patients.
Summary: The study aimed to evaluate the safety and effectiveness of the therapeutic vaccine RUTI® in treating tuberculosis (TB) in an experimental mouse model, either alone or in combination with standard TB chemotherapy. RUTI® is a vaccine composed of Mycobacterium tuberculosis (Mtb) cell-wall fragments. The researchers tested RUTI® in a murine TB model, comparing its efficacy with standard TB chemotherapy (isoniazid, rifampicin, ethambutol, and pyrazinamide). The results showed that RUTI® significantly reduced pulmonary damage and bacterial burden in the lungs and spleen. When combined with chemotherapy, RUTI® further decreased lung damage and bacillary load, while increasing the immune response against specific Mtb antigens. This study suggests that RUTI® could be a potential adjunct therapy for TB treatment, encouraging further research in human TB patients.
To view the online publication, please click here: